|Year : 2021 | Volume
| Issue : 3 | Page : 124-125
Ventilation with the noble gas argon in an in vivo model of idiopathic pulmonary arterial hypertension in rats
Daria De Giorgio1, Aurora Magliocca1, Francesca Fumagalli1, Deborah Novelli1, Davide Olivari1, Lidia Staszewsky1, Roberto Latini1, Giuseppe Ristagno2
1 Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
2 Department of Pathophysiology and Transplantation, University of Milan; Department of Anesthesiology, Intensive Care and Emergency Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
|Date of Submission||09-Nov-2020|
|Date of Decision||15-Nov-2020|
|Date of Acceptance||18-Nov-2020|
|Date of Web Publication||27-Apr-2021|
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
De Giorgio D, Magliocca A, Fumagalli F, Novelli D, Olivari D, Staszewsky L, Latini R, Ristagno G. Ventilation with the noble gas argon in an in vivo model of idiopathic pulmonary arterial hypertension in rats. Med Gas Res 2021;11:124-5
|How to cite this URL:|
De Giorgio D, Magliocca A, Fumagalli F, Novelli D, Olivari D, Staszewsky L, Latini R, Ristagno G. Ventilation with the noble gas argon in an in vivo model of idiopathic pulmonary arterial hypertension in rats. Med Gas Res [serial online] 2021 [cited 2021 Jun 15];11:124-5. Available from: https://www.medgasres.com/text.asp?2021/11/3/124/314333
Idiopathic pulmonary arterial hypertension (PAH) is a rare and progressive disease with high morbidity and mortality. Endothelial dysfunction and obstructive vascular remodeling produce sustained high pressure in the pulmonary arterial system resulting in increased right ventricular (RV) afterload and hypertrophy. Maladaptive response to the elevated pulmonary vascular resistance (PVR) can promote RV failure and ultimately death. Although long-term survival in patients with PAH has significantly improved in the past two decades, the clinical burden of the disease is still high, with a 5-year survival rate of approximately 50%. Therapies for PAH are mainly endothelin antagonists, for example bosentan (a non-selective endothelin-1 (ET-1) receptor antagonist) and ambrisentan (a selective ETA receptor antagonist). In general, vasodilators that improve hemodynamics and functional capacity ameliorating the quality of life have no definitive curative effects. Recently, the noble gas Argon (Ar) has been proposed as a pulmonary vasodilator agent.
Suleiman et al. for the first time described the vasodilating effects of 74% Ar in rat isolated perfused lungs and precision-cut lung slices from both rats and humans. In this ex vivo and in vitro study, the authors showed that treatment with Ar attenuates ET-1 induced vasoconstriction. Specifically, the effects of Ar can be summarized as:
- Attenuation of the increase in capillary pressure and post-capillary resistance induced by ET-1 in isolated perfused lungs, although no reduction in pulmonary arterial pressure or PVR was detected;
- Reduction of ET-1-induced contraction in both rat and human pulmonary arteries, measured as intra-vessel area extension in the precision-cut lung slices;
- Reduction ET-1-induced lung edema in rat isolated perfused lungs.
In the present study we investigated whether prolonged inhalation of 70% Ar has pulmonary vasodilating effects in an in vivo rat model of severe PAH.
All procedures involving animals and their care fulfilled national and international laws and policies (approval No. 202/2017-PR; approval date 6/3/2017; Legislative Decree No. 76/2014-B, Italian Ministry of Health). PAH was induced in 11 male Wistar rats (6–8 weeks, Charles River, Calco, Italy) weighting 306 ± 6 g by subcutaneous injection of 60 mg/kg monocrotaline (Sigma-Aldrich, Inc., St. Louis, MO, USA), as previously described.
Four weeks after monocrotaline injection, animals were randomized into: Ar, 24-hour inhalation of 70% Ar and 30% oxygen (O2) (n = 5) or AIR, 24-hour inhalation of room air (n = 4). Ar mixture (SIAD, Bergamo, Italy) was delivered through a 200-L chamber prefilled with the gas (temperature 24–26°C, standard light-dark cycle). Total gas flow was measured with a flowmeter (1–10 L/min; Ohmeda, Selectatec, Sacem s.r.l, Cremona, Italy). Soda lime was added as a CO2 scavenger.
After 24-hour treatment, echocardiography was performed (Arietta V70, Hitachi-Aloka, Milano, Italy) inside the chamber with the animals anesthetized. As previously described, pulsed-wave Doppler of pulmonary outflow was recorded in parasternal short-axis view at the level of the great vessels and pulmonary artery acceleration time was measured as the time of systolic flow to peak pulmonary outflow velocity. The RV stroke volume (RVSV) and cardiac output (RVCO) were calculated by the formulas: RVSV = π × (RV outflow tract/2) × RV outflow tract velocity time, RVCO = SV × heart rate. RV catheterization (Millar SPR71, AD Instruments Ltd., Oxford, UK) was performed through the right jugular vein during 70% Ar inhalation delivered by a nose mask. RV systolic pressure was measured as surrogate of pulmonary artery systolic pressure. Before euthanasia, blood was collected (0.3 mL) for the measurement of plasma concentrations of N-terminal proatrial natriuretic peptide by a validated enzyme-linked immunosorbent assay kit (Biomedica BI-20892, Vienna, Austria). Rats were then euthanized, and lungs were excised, weighted and wet-to-dry ratio was calculated. Data are shown as mean ± standard error or median and [Q1–Q3]. Student’s t-test or Mann-Whitney U test was used as appropriate.
Nine of eleven animals survived until the end of the experiment (29 days). Two rats died 26 days after monocrotaline injection, during the development of PAH. Echocardiographic variables showed a mild not significant improvement in Ar group compared to AIR group (pulmonary artery acceleration time, Ar: 17.7 ± 0.6 ms vs. AIR: 14.6 ± 2.3 ms, P = 0.2; RVCO, Ar: 69.6 ± 7.0 mL/min vs. AIR: 60.3 ± 18.9 mL/min, P = 0.6; RVSV, Ar: 0.19 ± 0.0180 mL vs. AIR: 0.15 ± 0.035 mL, P = 0.3). RV systolic pressure slightly decreased in Ar group compared to AIR group (Ar: 87.6 ± 10.1 mmHg vs. AIR: 101.8 ± 17.7 mmHg, P = 0.5). The median plasma concentration of N-terminal proatrial natriuretic peptide moderately decreased in Ar group compared to AIR group (Ar: 2.2 nM vs. AIR: 4.2 nM, P = 0.7). No differences between groups in the lungs wet-to-dry ratio were found (Ar: 5.0 ± 0.1 vs. AIR: 4.9 ± 0.1, P = 0.8).
To our knowledge, this is the first report studying in vivo the pulmonary hemodynamic effects of Ar inhalation in an animal model of PAH. No Ar-induced pulmonary vasodilating properties were shown, despite encouraging data from earlier investigations in ex vivo models.
Besides the proven neuroprotective effect of Ar, its vasodilating effect in lung vessels is still debated. Earlier in vivo study showed no hemodynamic effect on both systemic and pulmonary circulation in healthy pigs subjected to 4 hour ventilation with 70% Ar in O2. Similarly, ventilation with Ar did not change significantly hemodynamics, including PVR, and respiratory variables before and after lung transplantation in pigs compared to control ventilation with N2/O2. These findings are consistent with our previous observations in a swine model of cardiac arrest and cardiopulmonary resuscitation where ventilation with Ar did not affect pulmonary capillary wedge pressure, pulmonary arterial pressure, CO and thus the deriving PVR (Ar: 4.0 ± 0.4 vs. AIR: 3.1 ± 0.4, P = 0.2, after 4 hours of ventilation) compared to ventilation.
Despite the current study proves only a mild and/or no vasodilating effects of Ar ventilation, no clear detrimental effect has been detected also in an established rat model of PAH. This important observation will eventually justify further investigation of this novel approach in terms of dose and timing of administration from the onset of the disease.
As the main limitation of the study, we acknowledged that little different O2 concentration was used in Ar and AIR groups (30% and 21% respectively).
In conclusion, this in vivo study showed a lack of effects on pulmonary hemodynamics in PAH. The confirmed absence of detrimental effects of Ar treatment in this setting strongly supports other investigations in organ preservation and its potential clinical applicability in other pathological conditions.
Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.
Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.
Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
| References|| |
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol
Suleiman S, Klassen S, Katz I, et al. Argon reduces the pulmonary vascular tone in rats and humans by GABA-receptor activation. Sci Rep
Novelli D, Fumagalli F, Staszewsky L, et al. Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. Eur J Pharmacol
Martens A, Ordies S, Vanaudenaerde BM, et al. A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemia-reperfusion injury. Med Gas Res
Cucino A, Ruggeri L, Olivari D, De Giorgio D, Latini R, Ristagno G. Safety of ventilation with an argon and oxygen gas mixture. Br J Anaesth
Fumagalli F, Olivari D, Boccardo A, et al. Ventilation with argon improves survival with good neurological recovery after prolonged untreated cardiac arrest in pigs. J Am Heart Assoc